-
Listing
Strengthening Europe’s strategic autonomy through capital marketsCzechoslovak Group lists on EuronextLees meerWorld’s largest defence IPO ever recorded.
Learn more about Euronext’s initiatives to enhance financing and visibility for European aerospace and defence companies -
Handelsinformatie
Where European Government Bonds meet the futureFixed Income derivativesLees meerTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLees meerEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLees meerEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Lees meerThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLees meerThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Lees meerShaping capital markets for future generations
ASIT biotech
11/05/2016
ASIT biotech zet eerste stappen op de Beurs
Euronext Brussel en Parijs hebben vandaag, 11 mei 2016, ASIT Biotech ontvangen, een Belgische vennootschap gespecialiseerd in de behandeling van allergieën. Thierry Legon, CEO van ASIT Biotech, heeft de openingsbel geluid om de eerste notering te vieren van het bedrijf dat 23.5 miljoen heeft opgehaald tijdens deze IPO.ASIT biotech treedt op deze manier toe tot een gemeenschap van 77 bedrijven die gespecialiseerd zijn in life sciences genoteerd op de Euronext markten.